Search results (6)
« Back to NewsNew study maps the crucial factors in inflammation control
8 May 2024
A Cell Reports study from the Target Discovery Institute and CAMS Oxford Institute provides an intricate time-resolved molecular map of different phases of NLRP3 inflammasome activation and unveils ubiquitin C-terminal hydrolase 1 (UCH-L1) as a modulator of NLRP3 inflammasome assembly and IL-1β production.
Novel processing enzyme for ISG15 discovered
8 December 2023
Researchers from the CAMS Oxford Institute and NDM Target Discovery Institute, including Prof Benedikt Kessler and Dr Adán Pinto-Fernández, have collaborated with the team of Dr Paul Geurink and Dr Aysegul Sapmaz from Leiden University to investigate an important interferon-stimulated gene, ISG15.
Mapping proteins in tumours to help understand cancer
30 November 2023
A group of researchers led by Dr Roman Fischer at NDM’s Target Discovery Institute and Centre for Medicines Discovery (CMD) has developed a method to study proteins in human tumours by creating detailed maps that show how much of each protein is present in different parts of the tissue.
Identifying the diagnostic markers of Japanese encephalitis
22 June 2023
Researchers from NDM’s Mahidol Oxford Tropical Medicine Research Unit, the Target Discovery Institute and Centre for Medicines Discovery, the University of Oxford’s Department of Biochemistry, and other collaborating organisations have found a nine-protein diagnostic signature in human cerebrospinal fluid that could discriminate between Japanese encephalitis and other brain infections.
New research opens new strategies for cancer therapeutics
13 February 2023
Researchers from NDM’s Target Discovery Institute and CAMS Oxford Institute, and the Department of Biochemistry uncovered at the molecular level how protein BIRC6 (a giant ubiquitin ligase) keeps cells alive.
New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy
18 October 2017
A multi-disciplinary research team from the Universities of Oxford, MRC LMB, Liverpool, Cancer Research UK and pharma (Forma Therapeutics) has performed structural studies of USP7 inhibitor-enzyme interactions, demonstrating that ubiquitin-specific proteases (USPs) are tractable drug targets for cancer and also other diseases.